New cancer drug enters first human tests for multiple tumor types
NCT ID NCT07369505
Summary
This early-stage study is testing a new drug called Sapu003 in people with advanced cancers that have spread or cannot be removed by surgery. The main goal is to find the safest and most effective dose, and to see how the body processes the drug. The study includes 27 adults with specific advanced cancers including breast, kidney, liver, and neuroendocrine tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SOCRU
RECRUITINGAdelaide, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.